Saturday 17 October 2026
Export PMCB’s income statement to Excel — free account
Nuvilex Inc.
PMCB Healthcare Biotechnology
In the quarter to July 2026, EPS grew 56.1% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.34
0.02
−5.56%
Follow PMCB
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Older periods | |
|---|---|---|---|---|---|
| (58.04%) | (54.48%) | (24.38%) | (28.07%) |
+8 more TTM periods Free account |
|
| (50.43%) | (45.54%) | (19.17%) | (19.88%) | ||
ROIC |
0.00% | 0.00% | (19.15%) | (13.46%) | |
Return on Tangible Assets |
(68.30%) | (63.42%) | (50.24%) | (51.50%) | |
Average Days of Receivables |
0.00 | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
(0.37) | (0.61) | (0.52) | (0.67) | |
Free Cash Flow |
(3.94) | (5.15) | (4.80) | (4.52) | |
| Other line items | |||||
Cash ROIC |
(6.79%) | (7.32%) | (8.19%) | (8.90%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.19 | 0.22 | 0.50 | 0.41 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.37) | (0.61) | (0.52) | (0.67) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026